Purpose: Adeno-associated virus serotype 2 (AAV2) has been shown to be effective in transducing inner retinal neurons, following intravitreal injection in several species. However, results in non-primates may not be predictive of transduction of human inner retina, because of differences in eye size and the specialized morphology of the high acuity human fovea. Here we studied inner retina transduction in the macaque, a primate with ocular characteristics most similar to human.
Introduction
Viral-mediated gene delivery has been extensively studied for retinal transduction 1, 2 for basic research e.g., 3 , and clinical applications e.g., 4, 5 . Adeno-associated virus (AAV) is a preferred viral vector due to its lack of pathogenicity, high transduction efficiency, and long-term transgene expression e.g., 2, 6, 7 , and it is typically administered by intravitreal injection to transduce inner retinal cells (e.g., ganglion and Müller cells). Of the many AAV serotypes that have been identified, serotype 2 is the most studied in retina 8, 9 .
Although animal models of viral mediated gene delivery to the retina are motivated by the development of gene therapy for human, the uniqueness of the human eye may make viral transduction studies in common mammalian models (e.g., rats, mice, rabbits) a poor predictor of transduction in humans. The macaque closely matches humans phylogenetically, as well as in structural features that may be important for retinal transduction, including eye size [10] [11] [12] , the configuration of the high-acuity fovea 13 , a thick nerve fiber layer (NFL) 14 and inner limiting membrane (ILM) 15 on the retinal surface. However, only a handful of studies have explored
AAV2 transduction in macaque eyes by intravitreal injection (Merigan WH, et al. IOVS
2008;49:ARVO E-Abstract 4514) 6, 16 , and they suggest that primate retina may have unique barriers to transduction that have not been identified in other animal models.
Here, we describe AAV2 mediated transduction of the macaque retina by intravitreal injection using green fluorescent protein (GFP) as a reporter. Because of the biological significance of human foveal vision 17, 18 , one focus of our study was to evaluate the efficiency and selectivity of AAV2 with different promoters for transducing inner retinal cells in the fovea, which are excellent targets for retinal gene therapy. To this end, various neuronal (hCx36, hCx36sh and hSYN) and ubiquitous (CBA, smCBA) promoters were evaluated. The GFP expression driven by those promoters was tracked over time with a fundus camera optimized to
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detect GFP fluorescence. When strong expression was reached, the subcellular localization of GFP expression was examined using fluorescence adaptive optics (AO) imaging e.g., 19 , which provides substantially higher resolution and sensitivity than fundus imaging. These in vivo imaging results were then confirmed with histology. We found dense ganglion cell transduction with the hCx36 promoter in primate fovea, as well as non-selective transduction of Müller and ganglion cells with the ubiquitous CBA promoter. Moreover, our results show that transduction patterns of AAV2 in the macaque eye by intravitreal injection is qualitatively similar to that in the smaller eye of a foveated new-world primate marmoset 20, 21 , yet significantly different from that seen in other species, and in particular rodent models.
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Methods
Subjects
Eight adult macaque monkeys, each weighing approximately 6 kg, with ages ranging from 3-11 years at the time of injection (Table S1 ), were used. Eyes and retinas were normal in all studied monkeys, except for one monkey with a history of ganglion cell loss from a cortical infection and two monkeys given intravitreal injections of microplasmin, which produces vitreoretinal detachment (see Supplementary Materials and Methods). Head-posts were implanted in monkeys used for AO imaging, as previously described 19 . All animal procedures were conducted according to the ARVO Statement for the Use of Animals and the guidelines of the Office of Laboratory Animal Care at the University of Rochester.
Viral vectors
Preparation of vectors AAV vectors were packaged and purified by standard methods 22 in the Flannery laboratory at the University of California, Berkeley. Briefly, AAV was packaged by triple transfection (Lipofectamine 2000, Invitrogen, Carlsbad, CA) of transfer and helper plasmids into AAV293 cells. After harvest, lysis, and iodixanol ultracentrifugation, the interphase between the 54% and 40% iodixanol fraction, and the lower three-quarters of the 40% iodixanol fraction were extracted and further purified by heparin affinity chromatography. The eluent was concentrated and buffer exchanged using an Amicon Ultra-15 centrifugal filter unit. Virus was washed three times with fifteen milliliters of sterile phosphate buffered saline (PBS) with 0.001% Tween.
Vector was then titered by quantitative PCR (QPCR) relative to standards.
Promoter and gene payload of AAV2 vector
The AAV vectors produced for this study were AAV2/2 (i.e. AAV2 inverted terminal repeat containing genomes packaged inside AAV2 capsid, termed AAV2 in this paper) carrying GFP (either the enhanced GFP (eGFP) or humanized GFP (hGFP)) transgene (see Table S1 ).
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One of the following five promoters ( 23 . The sequences of hCx36 and hCx36sh have not been described previously (Greenberg K, manuscript in preparation, 2010). The 2.8 kb (hCx36) and 1.8 kb (hCx36sh) fragments of the hCx36 promoter were cloned from human genomic DNA using standard molecular biology techniques and high fidelity polymerase chain reaction. The promoter fragments were then ligated into an AAV2 backbone vector containing GFP and the WPRE. All vectors were sequenced for PCR fidelity. The sequence of hSYN has been described by Kugler et al. 24, 25 .
Intravitreal injection Viral vector (40 -100 µl) was injected into the vitreous of each eye through the sclera approximately 3mm behind the limbus, using a 30-gauge needle, with precautions to avoid infection. The condition of the injected eyes was monitored closely for up to two weeks. Three eyes from two animals were pretreated by an intravitreal injection of 50 µg (in 100 µl distilled water) of recombinant microplasmin (Thrombogenics, Leuven, Belgium; see Table S1 ), a recombinant serine protease that is used to degrade the vitreo-retinal junction and produce posterior vitreal detachment in human eye 26 . These injections were given using identical procedures 5 days before the injection of viral vector.
In cases when both eyes were injected with vector, the second injection was performed less than one month after the first injection (Table S1) , to avoid immune inactivation of the second injection by antibodies against AAV2 from the first injection 27 . Serum antibody titer against AAV2 was measured in the Schaffer laboratory at UC Berkeley (see Supplementary Materials and Methods). We excluded from analysis one monkey that had a high serum antibody titer against AAV2 prior to virus injection (Table S1 ).
In vivo transduction evaluation
Fundus imaging
Color and fluorescence fundus images were taken of each studied retina using a TRC- 1A,B, 4A and 7) were calculated assuming that the distance between the fovea center and temporal edge of the optic disk is 11.8 degrees 28 .
AO imaging
The fluorescence adaptive optics scanning laser ophthalmoscope (FAOLSO) was used to image retinal neurons that expressed GFP in vivo, as previously described 19, 29 . During imaging :
where the D eye is the power of the macaque eye. For the animals used in this study, a normative eye power of 74.2 D was assumed 30 . 0.1 D corresponds to approximately 24 µm.
Histology
Ex vivo preparation For animals euthanized for histological analysis (see Table S1 ), eyes were enucleated from the animal immediately after euthanasia and fixed by immersion in 4% paraformaldehyde (in 0.1 M phosphate buffer). Retina, with pigment epithelium attached, was separated from sclera. Retinal whole-mounts were flattened on a glass slide by making several radial cuts at the 
Ex vivo confocal imaging
Ex vivo whole-mount and transverse sections were imaged using a confocal microscope 
Conversion between angular and retinal distances
Since in vivo fundus and AO images were measured in angular distance (degrees of visual angle), and ex vivo confocal imaging were measured in retinal distance (µm), we assume 223 µm in retinal distance for 1 degree in angular distance 31 . Converted values are quoted within parenthesis.
Results
AAV2 transduction in macaque eye occurred in fovea and peripheral retina, but not in central retina outside the fovea. Foveal transduction was more consistent across promoters than was peripheral transduction.
AAV2-hCx36-GFP transduces foveal ganglion cells, but not Müller cells.
Intravitreal injection of AAV2-hCx36-GFP resulted in a dense annulus of GFP expression around the fovea, clearly visible in vivo, as evaluated with either fundus or adaptive optics (AO) imaging ( Fig. 1 ; four eyes were tested, see Table S1 ). Figure 1A , and the expression has remained stable for more than 2.5 years after vector injection.
Through-focus AO images of the GFP expressing annulus showed a complete lack of GFP expression in Müller cells with the neuronal hCx36 promoter (Fig. 1D ,E). GFP-expressing cells in the inner portion of the annulus are in sharp view at deep focus (arrows in Fig. 1D ), but not at the superficial focus (arrows in Fig. 1E ), while GFP-expressing cells in the outer portion of the annulus are in sharp view at the superficial focus (arrowheads in Fig. 1E ), but not at the deep focus (arrowheads in Fig. 1D ). The deep focus image (Fig. 1D ) shows a few scattered cells within the foveal avascular zone (open triangle), which may be ganglion cells, as described by Grünert et al. 34 .
Ex vivo confocal images of retinal whole-mounts confirmed AAV2-hCx36-GFP transduction in foveal cells in the ganglion cell layer (GCL), but did not involve Müller cells.
Because ganglion cells comprise 95% of the neuronal cell population in the GCL in fovea (displaced amacrine cells are 5% or less 35, 36 (see also Curcio and Allen 13 for human retina), most of the GFP-expressing cells are ganglion cells. The inner edge of the GFP-expression annulus showed no expression of GFP in Müller cells below the ganglion cell layer (Fig. 2B ), confirming the in vivo observation (Fig. 1D,E) . The outer edge of the GFP-expression annulus also showed no intervening Müller cell processes between the individual cell somas in the ganglion cell layer (Fig. 2C,D) . GFP-expression was also visible in the inner plexiform layer (IPL), where the dendrites of transduced ganglion cells extend (Fig. 2B) . We also observed scattered GFP-expressing cell somas in the inner nuclear layer (INL), close to the IPL/INL border, which could be amacrine cells 37 (data not shown).
While AAV2-hCx36-GFP produced strong foveal transduction in normal eyes, no retinal transduction was seen in central retinal outside the annulus of foveal GFP (data not shown). In peripheral retina, we observed scattered transduction of cells in the GCL, especially along blood vessels (data not shown). GFP expression was also found in peripheral retina in eyes that received enzymatic vitreolysis with microplasmin prior to vector injection (see Methods, and Table S1 ). For the eye shown in AAV2-CBA-GFP transduced both ganglion cells and Müller cells in fovea and peripheral retina
Intravitreal injection of AAV2-CBA-GFP resulted in a disc of GFP expression centered on the fovea and extending to more than 1.5 degrees (~ 0.3 mm) eccentricity, which was clearly visible in vivo, as evaluated by fundus and AO images ( Fig. 4A-C ; one eye was tested, see Table   S1 ). GFP expression in axon bundles appeared less intense with the CBA promoter than with the hCx36 promoter and could barely be seen in the fundus image ( However, GFP-expressing axon bundles, as well as individual retinal cells, were clearly seen in AO images (Fig. 4B,C) . GFP expression produced by AAV2-CBA-GFP took much longer to develop than AAV2-hCx36-GFP, with no funduscopically visible transduction even at 4 months after viral injection, and the next examination at 10 months showed stable expression. However, the lower titer of the AAV2-CBA-GFP relative to the AAV2-hCx36-GFP precludes comparison of transduction efficiency of CBA and hCx36 promoters (see Table S1 ).
Through-focus AO images showed that foveal Müller cells are densely transduced. The three dimensional morphology of the GFP-expressing Müller cells and distribution of ganglion cells in the foveal region can be seen through a series of AO images across retinal depths from outer retina towards inner retina ( Fig. 4D-G) . In Figure 4D , Müller cell processes at the outer retina are in focus, while in Figure 4G , more superficial ganglion cell somas are in focus. The lateral displaced processes of the Müller cells, and their soma are best visualized in the intermediate focuses (respectively Fig. 4E,F) . These GFP-expressing Müller cells are responsible for the solid, disk-like appearance of the GFP expression in the fundus image (Fig. 4A ).
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Ex vivo confocal images confirm that AAV2-CBA-GFP transduces both foveal ganglion cells and Müller cells (Fig. 5) . As shown in the transverse section through the GFP-expressing disc centered on the fovea (Fig. 5B) Shorter promoters were ineffective in normal retinas, but produced transduction in retinas with ganglion cell loss, or enzymatic vitreolysis.
Since AAV vectors have a limited packaging capacity, we explored the use of shorter neuronal and ubiquitous promoters to drive GFP expression in the primate retina.
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We examined transduction by two short neuronal promoters -hSYN 24 and the shortened hCx36 promoter (hCx36sh) -in normal and diseased eyes with ganglion cell loss (one eye for each condition; see Table S1 and Fig. S1 ), and compared both to transduction with hCx36 promoter. As shown by fundus images (Fig. 7A,C) , intravitreal injection of AAV2 with neither promoter produced visible GFP expression in normal retinas over durations that exceeded the time needed for transduction by hCx36, but in both cases (at comparable titer; see Table S1) produced visible GFP expression (Fig. 7B,D) in eyes with loss of ganglion cells (see Fig. S1A ).
However, the lower titers of the AAV2-hSYN-GFP and AAV2-hCx36sh-GFP than the AAV2-hCx36-GFP preclude comparison of transduction efficiency of the two short neuronal promoters to hCx36 promoter (see Table S1 ).
We also examined the transduction by the short CBA promoter (smCBA) in a normal eye and an eye that received enzymatic vitreolysis with microplasmin (see Methods) prior to vector injection (one eye for each condition; see Table S1 ), and compared both to the transduction with CBA promoter (at comparable titer; see Table S1 ). As shown by fundus images (Fig. 7E,F) , intravitreal injection of AAV2-smCBA-GFP produced no visible GFP expression in normal retina (Fig. 7E ) over a duration that exceeded the time needed to produce expression with the full-length CBA promoter, but produced visible GFP expression in the eye pre-treated with microplasmin ( Fig. 7F) . For the latter, the appearance of foveal transduction (Fig. 7F ) was similar to that of the full-length CBA promoter (Fig. 4A) , and we confirmed by histology that both foveal ganglion cells and Müller cells were transduced (data not shown). Besides foveal transduction, prominent transduction in far peripheral ganglion cells was also visible in the fundus image (Fig. 7F) as dense GFP expression in axons entering the optic disc from nasal retina, and we verified by histology that both Müller cells and ganglion cells at the distal edge of far peripheral retina are transduced (data not shown).
Discussion
This study found that intravitreal injection of AAV2 into the macaque eye produced dense ganglion cell and Müller cell transduction only in a narrow region surrounding the fovea, with no transduction in central retina beyond the fovea and little or no transduction in peripheral retina. This result differs from the more uniform transduction reported after intravitreal injection in other species, including rodents e.g., 8, 40 , and raises the question of how well studies in nonprimates are predictive of gene therapy results in humans.
What limits transduction of macaque inner retina?
The limited transduction we observed may be due to the physical barriers posed by the anatomy of the macaque retina, such as the nerve fiber layer (NFL) and inner limiting membrane (ILM) which lie along the surface of the retina, between ganglion cell layer and vitreous.
Thickness variation of the NFL across the retina is consistent with the transduction patterns observed in this study. There is a complete absence of nerve fiber layer covering the foveal retinal location where inner retinal cells were transduced (see Figs. 1B and 4A ). Outside the fovea, superior and inferior to the optic disc, NFL thickness can reach a maximal thickness of more than 200 µm in macaque retina, and over 300 µm in human retina 14 . These are the regions where no transduction was observed. When nerve fiber layer thickness was greatly reduced in retinas with ganglion cell loss, inner retina transduction was enhanced ( Fig. 7B,D; see Fig. S1 ).
A similar phenomenon has been reported in degenerated rodent retina 41 . Together these results suggest enhanced transduction in the disease compromised retina, an advantage from the gene delivery perspective.
Although the ILM is thin compared to the NFL, its thickness is inversely related to the inner retina transduction efficiency observed in this study. Macaque (and human) ILM is thinnest in the fovea, where transduction is best, moderately thicker in the far peripheral retina, where
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expression was modest, and thickest in posterior retina near the fovea, where almost no transduction was observed 15 . Furthermore, the ILM is thinner above retinal vessels 15 , where we observed focal transduction of retinal cells along blood vessels at eccentricities beyond about 30 degrees (data not shown). Microplasmin, which disrupts the border between vitreous and ILM, increased transduction by AAV2-hCx36 and AAV2-smCBA in far peripheral retina where the ILM is relatively thin, similar to the increased transduction in rodent when the ILM was disrupted by a protease 42 . The human and macaque ILM are very similar 15 , and thus the inner limiting membrane will most likely be a barrier to AAV mediated gene delivery in humans.
The pattern of foveal transduction could also reflect other features of the primate retina that interact with AAV2 capsids, such as the distribution of cell surface receptors, since AAV2 binds selectively to heparin sulfate proteoglycan, and three co-receptors [43] [44] [45] [46] [47] . The topographical distribution of these receptors has not been measured in macaque retina. However, the dense transduction at the fovea indicates that promoter selectivity is not the basis for a lack of transduction in other areas of retina.
Which animal models are optimal for developing human gene therapy?
The wide variety of animal models used in gene therapy research each fills an important role. Rodents (e.g., mice) are widely used species well suited for genetic manipulations, whereas dogs and cats provide several unique models of retinal degeneration and greater similarity to human retina due to the large eye size and higher acuity area centralis. The non-human primate is better suited than the above species for predicting transduction in humans because of the unique morphology of the retina in species that have a fovea.
Recently, transduction of inner retina by intravitreal injection was studied in one nonhuman primate, the New World marmoset 20 , using an AAV2 virus with either the CAG (hybrid
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CMV early enhancer/chicken β-actin) or CMV (human cytomegalovirus immediate-early gene) promoter 21 . The marmoset has a small eye, with an average axial length of 11 mm 48 , substantially smaller than that of macaque (18 mm) 49 and human (24 mm) 50 . Marmosets have a well-developed fovea, similar to that of macaque and human 51 in both overall shape and the extent of ganglion cell displacement away from the foveal center.
However, the transduction of marmoset retina observed by Ivanova et al. 21 was quite different from that observed in the macaque in our laboratory in three respects: cellular selectivity, the spatial pattern of transduction across the retina, and the depth of transduction through the retina. The CBA promoter used in the present study and the CAG promoter used in the marmoset study of Ivanova et al. 21 are similar 23 . Despite this similarity, the macaque We speculate that these differences between macaque and marmoset could be due to both species differences in viral tropism and a difference in the topology of a physical barrier, such as the ILM, which has not been studied in marmoset. Given that macaque is closer to human in evolutionary lineage 52 , and the great similarity in physical attributes of the two species, such as eye size 53 and ILM thickness 15 , it is likely that the transduction observed in macaques in this study provides a closer prediction of transduction by intravitreal injection in humans than that observed in marmoset. However, further research is needed to address this issue, due to differences in promoter, age, and viral titer between the studies in the two species.
Choice of vector and promoter for transducing macaque inner retina AAV2, with the hCx36 promoter, produced, selective transduction of foveal ganglion cells, but not Müller cells, making it a good choice to insert gene products into ganglion cells for neurophysiology studies or ganglion cell neuroprotection in diseases such as glaucoma.
However, the hCx36 promoter fragment used in this study is large (2.8 kb) and it occupies much of the 4.7 kb genomic capacity of AAV2 54 , leaving little space for transgenes substantially larger than GFP (0.7 kb). The CBA promoter (1.7 kb) is smaller than hCx36, and produces good GFP expression that could not be determined from the fundus images. This distinction was particularly evident in this study when visualizing ganglion cell transduction by CBA, which was clear in AO images (Fig. 4B-G) , but barely observable in fundus image (Fig. 4A ).
Implications of this study for human retinal gene therapy A significant issue in moving viral-mediated gene therapies for human retinal disease from small animal efficacy studies to clinical applications are potential differences between the eye and retina of the animal model and human (e.g., retinal cell-surface properties, promoter selectivity and anatomy of the retina). Studies in the ideal animal model, the macaque monkey, are severely limited by availability cost, and lack of appropriate disease models, but need to be carried out to develop successful retinal gene therapy for humans. This study demonstrates that barriers to transduction of inner retina in macaque are substantial, but also shows that the use of high-resolution, in vivo adaptive optics imaging greatly facilitates such investigation. Figure Legends A and B. Neuronal promoter, hSYN, produced no visible GFP expression after 4.5 months (A), but when injected into an eye with ganglion cell loss (B) an annulus of GFP expression was seen in less than 2 months (data not shown; instead a later fundus image after 11 month is shown for better image quality). The transduction pattern in B was similar to that shown in Figure 1A , but the intensity of GFP expression was lower.
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C and D. Shortened human connexin 36 promoter (hCx36sh) resulted in no visible GFP expression after 4.5 months (C; for comparison, less than 2 months was typically needed for transduction by the full-length hCx36 promoter). However, when injected into an eye with ganglion cell loss (D), a faint annulus of GFP expression around the fovea center was visible less than 3.5 months when the first fundus image was acquired (data not shown; instead a later fundus image after 4.5 months was shown for better image quality.) The transduction pattern in D was similar that shown in Figure 1A , but the intensity of GFP expression was lower.
E and F. Shortened CBA promoter (smCBA) resulted in no GFP expression after 15 months when injected into normal retina (E; for comparison, less than 10 months was needed for transduction by full-length CBA promoter). However, when injected into an eye that received enzymatic vitreolysis with microplasmin (F), GFP expression in fovea was visible in less than 4.5 months when the first fundus image was acquired (data not shown; instead a later fundus image after 10 months was shown for better image quality). The transduction pattern in F was similar to that shown in Figure 4A . 
